MedTrace Logo

Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.

NCT07664007 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-06-23

No results posted yet for this study

Summary

Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.

Conditions

Interventions

DIETARY_SUPPLEMENT

Eicosapentaenoic acid oral lipidic emulsion

1 sachet/day of 20 ml containing 3g EPA during 12 weeks

DIETARY_SUPPLEMENT

Pacebo oral lipidic emulsion

1 sachet/day of 20 ml of placebo during 12 weeks

Sponsors & Collaborators

  • Hospital Clínico Universitario Lozano Blesa

    collaborator OTHER

  • Solutex GC S.L.

    collaborator INDUSTRY

  • Instituto de Investigación Sanitaria Aragón

    lead OTHER

Principal Investigators

  • Angel Lanas Arbeloa, MD, PhD · University Hospital Lozano Blesa. IIS Aragón. CIBER de Enfermedades Hepáticas y Digestivas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2023-09-17
Completion
2025-06-20

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07664007 on ClinicalTrials.gov